Drug Profile
BMD 3151
Alternative Names: BMD-3151Latest Information Update: 28 Sep 2023
Price :
$50
*
At a glance
- Originator University of Arkansas System
- Developer BiologicsMD
- Class Antineoplastics; Recombinant fusion proteins
- Mechanism of Action Parathyroid hormone receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Bone metastases
Most Recent Events
- 28 Sep 2023 No recent reports of development identified for preclinical development in Bone metastases in USA (SC, Injection)
- 08 Sep 2021 BMD 3151 is still in preclinical trials for Bone metastases in USA (BiologicsMD pipeline, September 2021)
- 28 May 2020 No recent reports of development identified for preclinical development in Bone metastases in USA (SC, Injection)